Kenneth S Koblan Net Worth

What's Kenneth Koblan's mailing address?

Kenneth's mailing address filed with the SEC is 300 THIRD STREET, , CAMBRIDGE, MA, 02142.

Insiders trading at Alnylam Pharmaceuticals Inc

Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal a Kevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.

What does Alnylam Pharmaceuticals Inc do?

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.

Alnylam Pharmaceuticals Inc executives and stock owners

Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• John Maraganore,
  Chief Executive Officer, Director
• Jeffrey Poulton,
  Chief Financial Officer, Executive Vice President
• Laurie Keating,
  Executive Vice President, Chief Legal Officer, Secretary
• Yvonne Greenstreet,
  President, Chief Operating Officer
• Akshay Vaishnaw,
  President - Research and Development
• Dr. John M. Maraganore M.D., Ph.D.,
  CEO & Exec. Director
• Margaret Hamburg,
  Independent Director
• Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB,
  Pres, COO & Director
• Dr. Yvonne L. Greenstreet M.B.A., MBChB, MBA,
  Pres & COO
• Dr. Akshay K. Vaishnaw,
  Pres of R&D
• Jeffrey V. Poulton M.B.A.,
  CFO & Exec. VP
• Laurie Bartlett Keating J.D.,
  Exec. VP, Chief Legal Officer & Sec.
• Michael Bonney,
  Independent Chairman of the Board
• Phillip Sharp,
  Independent Director
• Marsha Fanucci,
  Independent Director
• Amy Schulman,
  Independent Director
• Steven Paul,
  Independent Director
• Colleen Reitan,
  Independent Director
• David Pyott,
  Independent Director
• Dennis Ausiello,
  Independent Director
• Michael W. Bonney B.A.,
  Exec. Chairman
• Olivier Brandicourt,
  Director
• Kevin Fitzgerald,
  Senior Vice President, Chief Scientific Officer
• Kelley Boucher,
  Chief Human Resource Officer, Senior Vice President
• Arianna Greco,
  Interim Chief Legal officer
• Mark Baglin,
  VP of Global Marketing
• Agnieszka Gallagher,
  Chief Ethics & Compliance Officer
• Christine Regan Lindenboom,
  Sr. VP of Investor Relations & Corp. Communications
• Dr. Alfred W. Boyle Ph.D.,
  Chief Technical Operations & Quality Officer
• David Alexandre C Gros,
  SVP, Chief Business Officer
• Kevin P Starr,
  Director
• Paul Schimmel,
  Director
• Sanofi,
  10% owner
• Michael Mason,
  VP, Finance and Treasurer
• John K Clarke,
  Director
• Barry E Greene,
  President
• Manmeet Singh Soni,
  Chief Financial Officer
• Carolyn R Bertozzi,
  Director
• Pushkal Garg,
  CMO & EVP Dev & Med Affairs
• Peter N Kellogg,
  Director
• Venture Management Co Iii L...,
  10% owner
• Victor J Dzau,
  Director
• Agnovartis Pharma Ag Novartis,
  
• Venture Management Co Iii L...,
  
• Peter Barrett,
  Director
• Christoph H Westphal,
  Director
• Venture Fund V Lpatlas Vent...,
  
• Venture Management Co Iii L...,
  
• Ii Lp Chp,
  10% owner
• Kenneth S Koblan,
  Chief Scientific Officer
• Laurence Reid,
  SVP, Chief Business Officer
• Vicki L Sato,
  Director
• Management Ltd Abingworth,
  10% owner
• John A Jr Schmidt,
  SVP, Chief Scientific Officer
• Patricia L Allen,
  VP Finance and Treasurer
• Venture Fund V Lpatlas Vent...,
  
• John E Berriman,
  Director
• Vincent J Miles,
  Senior VP Business Development
• James L Vincent,
  Director
• Venture Fund V Lpatlas Vent...,
  
• Edward M Scolnick,
  Director
• Tolga Tanguler,
  EVP, Chief Commercial Officer
• Charles Elliott Sigal,
  Director